Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome
about
A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic SyndromeRituximab for nephrotic syndrome in children.American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximabRituximab for troublesome cases of childhood nephrotic syndrome.Rituximab Treatment for Nephrotic Syndrome in ChildrenA series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.Drug discovery in focal and segmental glomerulosclerosisSingle dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Recent advances in understanding and treating nephrotic syndrome.Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.Immunopathogenesis of idiopathic nephrotic syndrome with relapse.Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art.Regulatory T cells and minimal change nephropathy: in the midst of a complex network.Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.Emerging Agents for the Management of Nephrotic Syndrome: Progress to Date.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.Fatal rituximab-associated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome.Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome.Low-dose ofatumumab for rituximab-resistant nephrotic syndrome.A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population.Busy BsIs there clinical value in measuring suPAR levels in FSGS?Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Effectiveness of rituximab in nephrotic syndrome treatment.Prospects for Precision Medicine in Glomerulonephritis Treatment.Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
P2860
Q28548569-9680C450-B0DB-4CB2-A81A-F6020BA07696Q33555088-DE5A03BF-A3C9-484F-9FF0-1C881DEFA793Q33571864-20A99AAB-0E1C-45DD-ADE4-5577C414B5BEQ34130591-3A0CF098-F0CB-4536-99BD-7F902978057EQ34683518-981329F0-07F7-430B-AEB3-58C1864EB225Q35113681-9AAF0032-907C-419B-8B77-D74D5CAACE9BQ35674857-26476BB2-AAB4-4723-AA13-48631317BE79Q36003160-E2CEDF72-DF8C-486B-9B11-43A908613394Q36770915-CAC99B6C-4152-46F3-926F-8B11A50ECC3FQ36924116-1A3AEC93-620D-401C-A1D4-C0722CD7A59AQ37108328-152A7DAF-4DD9-4762-945E-B4FB8F411790Q37261621-5639AC58-7705-4CF6-BE26-1F2840919640Q37635783-84245A77-15C6-4137-A6FB-708CD7004E6AQ37670299-F9CB56B4-B417-4C55-9DBC-EFDB5A0B3245Q37728395-ACEE27B2-E57C-436E-8877-7352512EFA72Q37742644-F2A24B5C-0C70-4362-A184-1FB64E55249BQ38276417-0705F57A-46C5-4D30-BC7E-61FB57673F2DQ38543132-C627D424-9F73-4B8D-996A-69D98AAC90DBQ38622603-21FCC280-9F4D-4545-84D4-7491F6851AB8Q38662074-F1BA50D3-6995-4444-B7E9-AB9FE3D0B30DQ38679589-86CCEDD7-C92E-451A-BDF8-093CF642A9A9Q38701126-CF2A9686-EC6B-477A-BA6A-F4751BB2B679Q38805701-49179273-5B99-4BF4-8F37-A3006118A2B4Q38895019-15534F76-C4E0-4FE0-9D0A-182458C6B1EBQ38896218-82EC945D-0C9A-435C-A872-D856111ECA93Q39440837-E28256EB-83B9-4A45-859B-C967C987F500Q39456170-33F92AB0-A4E1-462A-A602-69EA5644D5B8Q40572300-6B7E4FF9-4A0E-434D-A21C-C5CDEEA82558Q41124267-A497028B-379F-42A0-8A15-09C925C12AA8Q41269163-114B7401-9112-404A-A2EB-8589F539E694Q41387077-FE57D845-FE03-4872-A6AE-AEC75F856493Q41728530-91659379-A99C-4651-ADAB-A32241EEF99CQ42376931-D7E5841E-0407-48DF-B2AF-79FA6E9F73BDQ42754554-FA05EF6C-F22B-406D-84DC-0EE90E04C0AEQ43063370-DCC5C116-5101-4AFD-A403-9F7E52F0BF18Q43506114-07244857-2804-443B-8319-9ED34B5A7F4EQ46250643-E1F8C693-83BB-47CA-965C-5DD7387BDC4FQ47107669-AEBD07B6-8502-4F19-90C3-4C2D16A5562EQ49300308-8B1A40C6-E540-496E-AB6D-74759A22BF89Q50047399-A7CBF486-5ACA-40AB-863F-F071B7B9AD25
P2860
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome
@en
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome.
@nl
type
label
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome
@en
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome.
@nl
prefLabel
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome
@en
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome.
@nl
P2093
P2860
P50
P356
P1433
P1476
Rituximab is a safe and effect ...... idiopathic nephrotic syndrome
@en
P2093
Alberto Magnasco
Alessandro Ponticelli
Alessia Fornoni
Antonello Pani
Changli Wei
Chiara Siciliano
Corrado Murtas
Daniel Muruve
Felice Sica
Francesco Scolari
P2860
P2888
P304
P356
10.1038/KI.2013.211
P407
P50
P577
2013-06-05T00:00:00Z